Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Blood (2022) 139 (16): 2471–2482.

https://doi.org/10.1182/blood.2021015161

Published: 2022

Includes: Supplemental data

Journal Articles

Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia

Keith Woodley, Laura S Dillingh, George Giotopoulos, Pedro Madrigal, Konstantinos Tzelepis, Celine Philippe, Kevin Rattigan, Ryan Asby, Vilma Dembitz, Aoife S.M. Magee, Gudmundur Helgason, Kevin Rouault-Pierre, George S. Vassiliou, Brian J.P Huntly, Paolo Gallipoli

Blood (2021) 138 (Supplement 1): 508.

https://doi.org/10.1182/blood-2021-148489

Published: 2021

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2021-152215

Published: 2021

Journal Articles

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Blood (2021) 138 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2021-145002

Published: 2021

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Blood (2021) 138 (Supplement 1): 608.

https://doi.org/10.1182/blood-2021-150766

Published: 2021

Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Blood (2018) 132 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2018-99-117089

Published: 2018

Journal Articles

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Rosemary Gale, PhD, David C. Linch, Brian J.P Huntly, Elli Papaemmanuil, PhD, Paresh Vyas, Alan K. Burnett, MD, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 664.

https://doi.org/10.1182/blood-2018-99-116482

Published: 2018

Journal Articles

Single Cell RNA-Seq Characterises Pre-Leukemic Transformation Driven By CEBPA N321D in the Hoxb8-FL Cell Line

Moosa Qureshi, MBBS, MRCP, Fernando Calero-Nieto, Iwo Kucinski, Sarah Kinston, George Giotopoulos, Dean Pask, Rebecca Hannah, Evangelia Diamanti, Xiaonan Wang, Reiner Schulte, Chiara Cossetti, Anthony R Green, Brian J.P Huntly, Berthold Gottgens

Blood (2018) 132 (Supplement 1): 3887.

https://doi.org/10.1182/blood-2018-99-110626

Published: 2018

Journal Articles

Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia

Faisal Basheer, MBBChir, MA, George Giotopoulos, PhD, Eshwar Meduri, PhD, Haiyang Yun, PhD, Milena Mazan, PhD, Olivia Sheppard, Daniel Sasca, MD, Malgorzata Gozdecka, PhD, George S. Vassiliou, MD PhD, Brian J.P Huntly

Blood (2017) 130 (Supplement 1): 1215.

https://doi.org/10.1182/blood.V130.Suppl_1.1215.1215

Published: 2017

Journal Articles

SRPK1 Is a Therapeutic Vulnerability in Acute Myeloid Leukemia through Its Effects on Alternative Isoforms of Epigenetic Regulators Including BRD4

Konstantinos Tzelepis, PhD, Etienne De Braekeleer, PhD, Isaia Barbieri, PhD, Vijay Baskar, PhD, Demetrios Aspris, MSc, Francisco Hermida Prado, PhD, Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Hannes Postingl, PhD, David Bates, PhD, Andrew Bannister, PhD, Brian J.P Huntly, Cristina Pina, MDDPhil, Allan Bradley, PhD, Kosuke Yusa, PhD, Tony Kouzarides, PhD, George S. Vassiliou, MD PhD

Blood (2017) 130 (Supplement 1): 781.

https://doi.org/10.1182/blood.V130.Suppl_1.781.781

Published: 2017

Journal Articles

Histone Acetyl-Transferase Kat2a Regulates Transcriptional Heterogeneity and Impacts Self-Renewal of Acute Myeloid Leukemia Cells in a Disease-Specific Manner

Ana Filipa Domingues, MSc, Rashmi Kulkarni, PhD, George Giotopoulos, PhD, Brian J.P Huntly, Sudhakaran Prabakaran, PhD, Cristina Pina, MDDPhil

Blood (2017) 130 (Supplement 1): 2486.

https://doi.org/10.1182/blood.V130.Suppl_1.2486.2486

Published: 2017

Journal Articles

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Dragana Milojkovic, MBBS, PhD, Richard E. Clark, Jennifer L Byrne, Brian J.P Huntly, Manoj Raghavan, Farooq A Wandroo, Sahra Ali, Belinda Austen, Jacqueline Ryan, Karsten Friedrich, Nicholas C.P. Cross, PhD, Adam J Mead, MD PhD

Blood (2017) 130 (Supplement 1): 2892.

https://doi.org/10.1182/blood.V130.Suppl_1.2892.2892

Published: 2017

Journal Articles

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

Blood (2017) 130 (Supplement 1): 1414.

https://doi.org/10.1182/blood.V130.Suppl_1.1414.1414

Published: 2017

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD

Blood (2016) 128 (22): 5223.

https://doi.org/10.1182/blood.V128.22.5223.5223

Published: 2016

Journal Articles

Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors

Brian J.P Huntly, MD PhD, Sarah Jayne Horton, BSc, PhD, George Giotopoulos, Haiyang Yun, MD PhD, Shabana Vohra, BSc, PhD, Olivia Sheppard, Bsc, PhD, Rachael Bashford-Rogers, PhD, Mamunur Rashid, PhD, Daniel Sasca, MD, Faisal Basheer, MBBChir, MA, Paolo Gallipoli, MD PhD, Jessica Okosun, Daniel James Hodson, MD PhD, Jude Fitzgibbon, Ming Du, David Adams

Blood (2016) 128 (22): 460.

https://doi.org/10.1182/blood.V128.22.460.460

Published: 2016

Journal Articles

Functional and Molecular Consequences of the Dnmt3aR882H Mutation in Acute Myeloid Leukaemia

Malgorzata Gozdecka, PhD, Milena M. Mazan, PhD, Vivek Iyer, Anna Farne, Eshwar Meduri, Ruben Bautista, Nicolas Walker, Anne C Ferguson-Smith, PhD, George S. Vassiliou, MD PhD, Brian J.P Huntly, MD PhD

Blood (2015) 126 (23): 2424.

https://doi.org/10.1182/blood.V126.23.2424.2424

Published: 2015

Journal Articles

Loss of BCOR Protein in Development of Acute Myeloid Leukaemia

Milena M. Mazan, PhD, Malgorzata Gozdecka, PhD, Emmanouil Metzakopian, PhD, Konstantinos Tzelepis, MSc, Brian J.P Huntly, MD PhD, George S. Vassiliou, MD PhD

Blood (2015) 126 (23): 2433.

https://doi.org/10.1182/blood.V126.23.2433.2433

Published: 2015

Journal Articles

A Crispr/Cas9 Drop-out Screen Identifies Genome-Wide Genetic Valnerubilities in Acute Myeloid Leukaemia

Blood (2015) 126 (23): 554.

https://doi.org/10.1182/blood.V126.23.554.554

Published: 2015

NARROW

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Single Cell RNA-Seq Characterises Pre-Leukemic Transformation Driven By CEBPA N321D in the Hoxb8-FL Cell Line

Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia

SRPK1 Is a Therapeutic Vulnerability in Acute Myeloid Leukemia through Its Effects on Alternative Isoforms of Epigenetic Regulators Including BRD4

Histone Acetyl-Transferase Kat2a Regulates Transcriptional Heterogeneity and Impacts Self-Renewal of Acute Myeloid Leukemia Cells in a Disease-Specific Manner

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors

Functional and Molecular Consequences of the Dnmt3aR882H Mutation in Acute Myeloid Leukaemia

Loss of BCOR Protein in Development of Acute Myeloid Leukaemia

A Crispr/Cas9 Drop-out Screen Identifies Genome-Wide Genetic Valnerubilities in Acute Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only